Abstract 18689: Impact of Glycosylated Hemoglobin Level on Six-month Angiographic and Two-year Clinical Outcomes in Diabetic Patients Undergoing Percutaneous Coronary Intervention with Drug-eluting Stents
Background: Higher level of glycosylated hemoglobin (HbA1C) is known to be associated with long term vascular complications of diabetic patients (pts). However, there have been limited data whether the association of high HbA1C level and the angiographic and long term clinical outcomes of diabetic pts undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DESs).
Methods: The study population consisted of 1838 consecutive diabetic pts underwent PCI with DESs enrolled from November 2005 to June 2008. Six-month angiographic and 2-year cumulative major clinical outcomes of diabetic pts with high HbA1C group (>6.5%, n= 403 pts, 81.4%) were compared with those of the control group (≤ 6.5%, n= 92 pts, 18.6%).
Results: The baseline clinical and procedural characteristics were similar between the two groups except higher total cholesterol and triglyceride levels in the high HbA1C group. Six-month angiographic and 2-year cumulative major clinical outcomes were not different between the two groups (Table).
Conclusions: In our study, higher level of HbA1C in diabetic pts was not closely associated with worse angiographic and clinical outcomes up to 2 years as compared to those of control group, suggestive of limited role of absolute blood sugar control in diabetic pts undergoing PCI with DESs.
- © 2010 by American Heart Association, Inc.